HIV testing and sexual risk reduction counseling in office-Based buprenorphine/naloxone treatment

Journal of Addiction Medicine

Volumn 7, Issue 6, 2013, Pages 410-416

  Edelman, J ^a,b   Moore, Brent A ^a,b   Caffrey, Sarah ^a,b   Sikkema, Kathleen J ^c   Jones, Emlyn S ^d   Schottenfeld, Richard S ^a,b   Fiellin, David A ^a,b   Fiellin, Lynn E ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

Buprenorphine; Counseling; HIV; Opioid related disorders; Risk reduction behavior

Indexed keywords

BUPRENORPHINE; NALOXONE;

ABSTINENCE; ADULT; ARTICLE; CONTROLLED STUDY; COUNSELING; FEASIBILITY STUDY; FEMALE; HIV TEST; HUMAN; MALE; OPIATE ADDICTION; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION; SEXUAL BEHAVIOR;

ADULT; BUPRENORPHINE; FEASIBILITY STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; NALOXONE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT EDUCATION AS TOPIC; RISK REDUCTION BEHAVIOR; SEX COUNSELING; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

EID: 84887971261     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e3182a3b603     Document Type: Article

References (40)

1. American Psychiatric Association. Diagnostic and Statistical Manual ofMental Disorders. Washington, DC: American Psychiatric Association, 2000
2. Bernstein E, Ashong D, Heeren T, et al. The impact of a brief motivational intervention on unprotected sex and sex while high among drugpositive emergency department patients who receive STI/HIV VC/T and drug treatment referral as standard of care. AIDS Behav 2012a;16(5): 1203-1216
3. Bernstein E, Heeren T, Winter M, et al. Long-term follow-up after voluntary human immunodeficiency virus/sexually transmitted infection counseling, point-of-service testing, and referral to substance abuse treatment from the emergency department. Acad Emerg Med 2012b;19(4):386-395
4. Booth RE, Campbell BK, Mikulich-Gilbertson SK, et al. Reducing HIVrelated risk behaviors among injection drug users in residential detoxification. AIDS Behav 2011;15(1):30-44
5. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55(RR-14):1-17; quiz CE11-14
6. Crits-Christoph P, Siqueland L, Blaine J, et al. The National Institute on D rug Abuse Collaborative Cocaine Treatment Study. Rationale and methods. Arch Gen Psychiatry 1997;54(8):721-726
7. Des Jarlais DC, Arasteh K, Perlis T, et al. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. AIDS 2007;21(2):231-235
8. Edelman EJ, Dinh AT, Moore BA, et al. Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians. J Addict Med 2012a;6(2):159-165
9. Edelman EJ, Dinh A, Radulescu R, et al. Combining rapid HIV testing and a brief alcohol intervention in young unhealthy drinkers in the emergency department: a pilot study. Am J Drug Alcohol Abuse 2012b;38(6):539-543
10. Fals-Stewart W, O'Farrell TJ, Freitas TT, et al. The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J Consult Clin Psychol 2000;68(1):134-144
11. Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict 2008;17(2):116-120
12. Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 2006;355(4):365-374
13. Fiellin DA, Weiss L, Botsko M, et al. Drug treatment outcomes among HIVinfected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr 2011;56(suppl 1):S33-S38
14. Gowing L, Farrell MF, Bornemann R, et al. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2011;8:CD004145
15. Hardin JW, Hilbe JM. Generalized Estimating Equations. Boca Roton, FL: Chapman & Hall, 2003
16. Haukoos JS, Hopkins E, Conroy AA, et al. Routine opt-out rapid HIV screening and detection of HIV infection in emergency department patients. JAMA 2010;304(3):284-292
17. Jenness SM, Neaigus A, Hagan H, et al. Heterosexual HIV and sexual partnerships between injection drug users and noninjection drug users. AIDS Patient Care STDS 2010;24(3):175-181
18. Kamb ML, Dillon BA, Fishbein M, et al. Quality assurance of HIV prevention counseling in a multi-center randomized controlled trial. Project RESPECT Study Group. Public Health Rep 1996;111(suppl 1):99-107
19. Kamb ML, Fishbein M, Douglas JM Jr, et al. Efficacy of risk-reduction counselingto prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA 1998;280(13):1161-1167
20. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010;375(9719):1014-1028
21. McLellan AT, Luborsky L, Cacciola J, et al. New data from the Addiction Severity Index: reliability and validity in three centers. J Nerv Ment Dis 1985;173(7):412-423
22. Metsch LR, Feaster DJ, Gooden L, et al. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health 2012;102(6):1160-1167
23. Neaigus A, Miller M, Friedman SR, et al. Sexual transmission risk among noninjecting heroin users infected with human immunodeficiency virus or hepatitis C virus. J Infect Dis 2001;184(3):359-363
24. Perlis TE, Des Jarlais DC, Friedman SR, et al. Audio-computerized selfinterviewing versus face-to-face interviewing for research data collection at drug abuse treatment programs. Addiction 2004;99(7):885-896
25. Prendergast ML, Urada D, Podus D. Meta-analysis of HIV risk-reduction interventions within drug abuse treatment programs. JConsultClin Psychol 2001;69(3):389-405
26. Project MATCH Research Group. Project MATCH (Matching Alcoholism Treatment to Client Heterogeneity): rationale and methods for a multisite clinical trial matching patients to alcoholism treatment. Alcohol Clin Exp Res 1993;17(6):1130-1145
27. Schottenfeld RS, Pakes JR, Kosten TR. Prognostic factors in buprenorphineversus methadone-maintained patients. J Nerv Ment Dis 1998;186(1):35-43
28. Semaan S, Neumann MS, Hutchins K, et al. Brief counseling for reducing sexual risk and bacterial STIs among drug users - results from project RESPECT. Drug Alcohol Depend 2010;106(1):7-15
29. Sobell LC, Sobell MB,Leo GI, et al. Reliability of a timelinemethod: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br J Addict 1988;83(4):393-402
30. Strathdee SA, Stockman JK. Epidemiology of HIV among injecting and noninjecting drug users: current trends and implications for interventions. Curr HIV/AIDS Rep 2010;7(2):99-106
31. Substance Abuse and Mental Health Services Administration. KAP KeysBased on TIP 40: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, MD: US Department of Health and Human Services, 2005
32. Sullivan LE, Barry D, Moore BA, et al. A trial of integrated buprenorphine/ naloxone and HIV clinical care. Clin Infect Dis 2006;43(suppl 4):S184-S190
33. Sullivan LE, Fiellin DA. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clin Infect Dis 2005;41(6):891-896
34. Sullivan LE, Fiellin DA. Narrative review: buprenorphine for opioiddependent patients in office practice. Ann Intern Med 2008;148(9):662-670
35. Sullivan LE, Moore BA, ChawarskiMC, et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat 2008;35(1):87-92
36. Sullivan LE, Moore BA, O'Connor PG, et al. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/ naloxone for the treatment of opioid dependence. Am J Addict 2010;19(1):53-58
37. Tetrault JM, Moore BA, Barry DT, et al. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. J Subst Abuse Treat 2012;43(4):433-439
38. TheNational Institute of Mental Health Multisite HIV Prevention Trial Group. The NIMH Multisite HIV Prevention Trial: reducing HIV sexual risk behavior. Science 1998;280(5371):1889-1894
39. Ware JE Jr, Kosinski M, Bayliss MS, et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995;33(4) (suppl):AS264-AS279
40. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30(6):473-483